L-carnitine administration has also been shown to improve markers of glycemic control in patients with NAFLD and diabetes, most likely by regulating the ratio of acetyl-CoA/CoA in the mitochondria and thereby the PDH flux. The gene discussed is PDP1; the disease is metabolic dysfunction-associated steatotic liver disease.